CYTEK BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.3 USD | +1.61% |
|
+1.29% | -30.92% |
| May. 08 | Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 Revenue $44.9M, vs. Street Est of $43.6M | MT |
| May. 08 | Transcript : Cytek Biosciences, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 209M | Sales 2025 * | 248M | Capitalization | 827M |
|---|---|---|---|---|---|
| Net income 2024 * | -13M | Net income 2025 * | 1M | EV / Sales 2024 * | 2.97 x |
| Net cash position 2024 * | 206M | Net cash position 2025 * | 227M | EV / Sales 2025 * | 2.42 x |
| P/E ratio 2024 * |
-82.2
x | P/E ratio 2025 * |
168
x | Employees | 637 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.29% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cytek Biosciences, Inc.
More recommendations
More press releases
| 1 day | +1.61% | ||
| 1 week | +1.29% | ||
| Current month | +4.83% | ||
| 1 month | +2.11% | ||
| 3 months | -27.08% | ||
| 6 months | +28.57% | ||
| Current year | -30.92% |
1 week
6.07
6.62
1 month
5.496.62
Current year
5.499.33
1 year
3.809.87
3 years
3.8028.70
5 years
3.8028.70
10 years
3.8028.70
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Yan
FOU | Founder | 61 | 14-11-30 |
Wen Bin Jiang
FOU | Founder | 60 | 14-11-30 |
Chris Williams
COO | Chief Operating Officer | 55 | 22-10-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donnie Hardison
BRD | Director/Board Member | 74 | 22-05-31 |
Deborah Neff
BRD | Director/Board Member | 71 | - |
Jack Ball
BRD | Director/Board Member | 77 | 18-11-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.19% | 0 M€ | -2.98% | - | |
| 0.11% | 0 M€ | 0.00% | - | |
| 0.11% | 0 M€ | +3.60% | ||
| 0.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 6.3 | +1.61% | 1,208,585 |
| 24-05-09 | 6.2 | -1.12% | 794,741 |
| 24-05-08 | 6.27 | -1.72% | 329,300 |
| 24-05-07 | 6.38 | -0.62% | 784,095 |
| 24-05-06 | 6.42 | +3.22% | 610,539 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
Calendar
2024-06-04
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
6.3
USD
Average target price
9.8
USD
Spread / Average Target
+55.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.92% | 827M | |
| +11.73% | 226B | |
| +9.53% | 188B | |
| +14.63% | 137B | |
| +27.47% | 108B | |
| +0.49% | 63.19B | |
| +13.73% | 52.26B | |
| +4.86% | 51B | |
| +7.72% | 43.89B | |
| +7.86% | 38.07B |
- Stock Market
- Equities
- CTKB Stock